Physician profile
Brandon Rowe
NPI 1083061048
$2,533.99
in general payments reported to CMS, 2019-2025
23 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $343 · 2021: $252 · 2022: $50.70 · 2023: $75.57 · 2024: $470 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671 · Education: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.73 |
| Education | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $431.92 | 2019-2025 | Tremfya |
| Abbvie INC. | $407.81 | 2019-2025 | Skyrizi |
| Novartis Pharmaceuticals Corporation | $203.85 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $189.44 | 2021-2025 | |
| Genzyme Corporation | $154.29 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $112.39 | 2024-2025 | Sotyktu |
| Organon LLC | $105.01 | 2024-2025 | Hadlima, Vtama |
| Regeneron Healthcare Solutions, INC. | $102.89 | 2020-2025 | Dupixent, Libtayo |
| Sanofi-Aventis U.S. LLC | $99.99 | 2020 | |
| Arcutis Biotherapeutics, INC. | $85.15 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $79.09 | 2020-2024 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $75.74 | 2020-2025 | Nemluvio |
| Dermavant Sciences, INC. | $73.08 | 2023-2024 | Vtama |
| Amgen INC. | $71.33 | 2024-2025 | Otezla, Otezla |
| Leo Pharma INC. | $63.48 | 2021-2025 | Anzupgo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $59.04 | 2020-2025 | Bimzelx |
| Pfizer INC. | $57.79 | 2021-2025 | |
| Botanix Sb INC | $49.94 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $28.01 | 2025 | Idacio |
| Helsinn Therapeutics (U.S.), INC. | $23.09 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $21.40 | 2019 | |
| Incyte Corporation | $20.16 | 2022 | |
| Merck Sharp & Dohme LLC | $19.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Rowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.